Skip to content
OpenCapital
Get started

King Pharmaceuticals KG Net income from discontinued operations

Net income from discontinued operations at other companies

Tiptree Inc. logo
Tiptree Inc.TIPT
——

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M—
Total equity$121.4M+2,773%
Total assets$964.2M—

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-71.3%
Enterprise value$184.93M-52.3%
P/E1.2×—
P/S1.6×-27.7×

Profitability

See full
Net margin131.5%—

Returns & leverage

See full
Return on equity90.8%—
Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's net income from discontinued operations.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's net income from discontinued operations?
King Pharmaceuticals (KG) reported net income from discontinued operations of -$703.25K in Q4 2025.